Treatment Strategy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. 2015

Shotaro Nakamura, and Takayuki Matsumoto
Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Uchimaru 19-1, Morioka 020-8505, Japan. Electronic address: shonaka@iwate-med.ac.jp.

Recent trends and current knowledge on the diagnosis and treatment strategy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma are reviewed. Helicobacter pylori infection plays the causative role in the pathogenesis, and H pylori eradication is the first-line treatment of this disease, which leads to complete remission in 60% to 90% of cases. A Japanese multicenter study confirmed that the long-term outcome of gastric MALT lymphoma after H pylori eradication is excellent. Treatment strategies for patients not responding to H pylori eradication including "watch and wait" strategy, radiotherapy, chemotherapy, rituximab immunotherapy, and combination of these should be tailored in consideration of the disease extent in each patient.

UI MeSH Term Description Entries
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae
D016481 Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease. Infections, Helicobacter,Helicobacter Infection,Infection, Helicobacter
D018442 Lymphoma, B-Cell, Marginal Zone Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder. Lymphoma, Mucosa-Associated Lymphoid Tissue,MALT Lymphoma,Marginal Zone B-Cell Lymphoma,Lymphoma of Mucosa-Associated Lymphoid Tissue,Mucosa-Associated Lymphoid Tissue Lymphoma,Lymphoma of Mucosa Associated Lymphoid Tissue,Lymphoma, MALT,Lymphoma, Mucosa Associated Lymphoid Tissue,Lymphomas, MALT,MALT Lymphomas,Marginal Zone B Cell Lymphoma,Mucosa Associated Lymphoid Tissue Lymphoma

Related Publications

Shotaro Nakamura, and Takayuki Matsumoto
March 2004, Clinical lymphoma,
Shotaro Nakamura, and Takayuki Matsumoto
January 2006, Internal medicine (Tokyo, Japan),
Shotaro Nakamura, and Takayuki Matsumoto
June 2010, Seminars in oncology,
Shotaro Nakamura, and Takayuki Matsumoto
May 2003, The American journal of gastroenterology,
Shotaro Nakamura, and Takayuki Matsumoto
October 2021, World journal of gastrointestinal oncology,
Shotaro Nakamura, and Takayuki Matsumoto
September 1998, Journal of the American College of Surgeons,
Shotaro Nakamura, and Takayuki Matsumoto
December 2022, Journal of clinical medicine,
Shotaro Nakamura, and Takayuki Matsumoto
December 2019, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi,
Shotaro Nakamura, and Takayuki Matsumoto
February 2021, Journal of gastroenterology and hepatology,
Shotaro Nakamura, and Takayuki Matsumoto
June 2007, Expert opinion on pharmacotherapy,
Copied contents to your clipboard!